The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)

Conditions

• Lower Respiratory Tract Infection

Eligibility Criteria

Sex

ALL

Age

18 Years - 99 Years

Healthy Volunteers

Not accepted

Interventions

• MeMed BV test — DIAGNOSTIC_TEST
  Following the MeMed BV test result, the clinician will decide whether or not to prescribe an antibiotic for your condition

Study Details

This is a Prospective, multi-center study enrolling adults subjects presented to the ED/Urgent care, with symptoms consistent with lower respiratory infection (LRTI). The reason of this study is to demonstrate the MeMed BV can help clinicians make decisions about using antibiotics in patients with lower respiratory track infections and see how it would impact clinical outcomes, antibiotics use, hospitalizations, ED clinicians find ways to improve health and medical care.

Key Dates

Start date

Jan 31, 2023

Status verified

Jan 2026

Primary completion

Feb 1, 2026

Completion

Feb 28, 2026

Study Design

Enrollment

1,316 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Arms

• Experimental: Adults with suspected Lower Respiratory Track Infection (LRTI)- The MeMed BV arm
  ED and urgent care center patients over the age of 18 years , with clinical suspicion of Lower Respiratory Track Infection. clinician will receive the BV result, this will include a recommendation regarding antibiotic treatment. A telephone FU call will be done at 28 (+/- 3) days after the day of consent to complete a short questionnaire regarding your current illness
• No Intervention: Adults with suspected Lower Respiratory Track Infection (LRTI)- The control arm
  ED and urgent care center patients over the age of 18 years , with clinical suspicion of Lower Respiratory Track Infection. clinician will not receive the BV result, and will treat according to standard of care. A telephone FU call will be done at 28 (+/- 3) days after the day of consent to complete a short questionnaire regarding your current illness

Primary Outcome Measure

To demonstrate MeMed BV® added value on top of standard of care in lowering unwarranted antibiotic prescribing in patients with LRTI in the ED/UCC. [ Time Frame: Through study completion, an average of 18 months ]

Locations (8)

Find similar trials in Jacksonville, FL

Related Studies

• Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
  PHASE3 · Recruiting · Ansun Biopharma, Inc. · Duarte, California
• Reducing Overuse of Antibiotics With Decision Support
  Recruiting · Vanderbilt University Medical Center · Oakland, California